Abstract
Collagens are key structural components of basement membranes, providing a scaffold for other components or adhering cells. Collagens and collagen-derived active fragments contribute to biological activities such as cell growth, differentiation and migration. Here, we report that collagen XV knock-out (ColXV KO) mice are resistant to experimental ischemic stroke. Interestingly, the infarcts of ColXV KO mice were as small as those of wild-type (WT) mice thrombolysed with recombinant tissue plasminogen activator (rtPA), the actual treatment for ischemic stroke. Importantly, there were no differences in the architecture of cerebrovascular anatomy between WT and ColXV KO mice. We found a twofold increase of the most potent pro-angiogenic factor, type A vascular growth endothelial factor (VEGF-A) in the ipsilateral cortex of rtPA-treated ischemic WT mice compared with untreated ischemic and sham-operated counterparts. A similar increase of VEGF-A was also found in both rtPA and untreated ischemic ColXV KO mice compared with sham ColXV KO mice. Finally, we evidenced that the levels of ColXV were increased in the plasma of WT mice treated with rtPA compared with untreated ischemic counterparts. Altogether, this study indicates that the lack ColXV is protective after stroke and that the degradation of endothelial ColXV may contribute to the beneficial effect of rtPA after ischemic stroke. The neuroprotection observed in ColXV KO mice may be attributed to the increased VEGF-A production following stroke in the ischemic territory.
Highlights
Stroke is a leading cause of death and long-term disability worldwide.[1]
Taking together all the limitations for the use of recombinant tissue plasminogen activator (rtPA), only 5% of ischemic stroke patients are eligible for rtPA-induced thrombolysis.[4]
Magnetic resonance imaging (MRI) images revealed that the lesion volume was significantly smaller in ColXV KO mice compared with WT mice (Figures 1a and b: 24.2 ± 2.5 mm[3] for WT mice and 16.3 ± 1.5 mm[3] for ColXV KO mice; P = 0.0179)
Summary
Stroke is a leading cause of death and long-term disability worldwide.[1]. Ischemic strokes represent 80% of cerebral strokes and result from the obstruction of a major cerebral artery by a thrombus or an embolus which reduces the blood flow in downstream targeted brain regions, leading to brain damage. The establishment of the primary ischemic lesion is followed by a series of secondary events that worsens tissue damage, including vascular, cellular and molecular events.[2] Nowadays, the only treatment for ischemic stroke is reperfusion with intravenous administration of recombinant tissue plasminogen activator (rtPA; Alteplase) within a strict time frame up to 4.5 h, leading to an improved functional recovery and reduced neurological deficits.[3] to its narrowed therapeutic window, rtPA increases the risk of intracerebral hemorrhagic transformations and is not efficient at degrading platelet-rich thrombi. Collagens are well-known to be critical extracellular components in vascular stability and functions. Some collagens such as ColXV, ColXVIII and ColXIX have been shown to be essential for motor axon guidance and neuromuscular development.[5,6,7] The structurally homologous. We showed that rtPA increased the presence of unbound ColXV in the plasma of wild-type (WT) mice after stroke
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
